Mutation Profile of Metastatic Castration-Resistant Prostate Cancer Patients Prior to Olaparib Treatment - EMA vs. FDA

被引：0
|
作者：
Dragos, Vita Setrajcic [1 ]
Stegel, Vida [1 ]
Klancar, Gasper [1 ]
Skerl, Petra [1 ]
Klasinc, Anja Zagozen [1 ]
Novakovic, Srdjan [1 ]
机构：
[1] Inst Oncol Ljubljana, Dept Mol Diagnost, Ljubljana, Slovenia
来源：
EUROPEAN JOURNAL OF HUMAN GENETICS | 2023年 / 31卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
P13.070.D
引用
收藏
页码：548 / 549
页数：2
相关论文
共 50 条
  • [31] Talazoparib for the Treatment of Metastatic Castration-resistant Prostate Cancer
    Qureshi, Zaheer
    Fatima, Eeshal
    Safi, Adnan
    Khanzada, Mikail
    Altaf, Faryal
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (04): : 206 - 214
  • [32] Evolution of the Treatment Paradigm for Patients with Metastatic Castration-Resistant Prostate Cancer
    Malik, Zafar
    Payne, Heather
    Ansari, Jawaher
    Chowdhury, Simon
    Butt, Mohammad
    Birtle, Alison
    Sundar, Santhanam
    Eswar, Chinnamani Vee
    Hughes, Simon
    Bahl, Amit
    ADVANCES IN THERAPY, 2013, 30 (12) : 1041 - 1066
  • [33] Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
    Rodriguez-Vida, Alejo
    Galazi, Myria
    Rudman, Sarah
    Chowdhury, Simon
    Sternberg, Cora N.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 3325 - 3339
  • [34] Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer
    Merseburger, Axel S.
    Bellmunt, Joaquim
    Jenkins, Cheryl
    Parker, Chris
    Fitzpatrick, John M.
    ONCOLOGIST, 2013, 18 (05): : 558 - 567
  • [35] Evolution of the Treatment Paradigm for Patients with Metastatic Castration-Resistant Prostate Cancer
    Zafar Malik
    Heather Payne
    Jawaher Ansari
    Simon Chowdhury
    Mohammad Butt
    Alison Birtle
    Santhanam Sundar
    Chinnamani Vee Eswar
    Simon Hughes
    Amit Bahl
    Advances in Therapy, 2013, 30 : 1041 - 1066
  • [36] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
  • [37] Enzalutamide for patients with metastatic castration-resistant prostate cancer
    Ramadan, Wijdan H.
    Kabbara, Wissam K.
    Al Masri, Hiba S. Al Basiouni
    ONCOTARGETS AND THERAPY, 2015, 8 : 871 - 876
  • [38] Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
    Ma, Yi
    He, Lijie
    Huang, Qianwen
    Zheng, Shuang
    Zhang, Zhiqiang
    Li, Hongshi
    Liu, Shuang
    BMC MEDICAL GENETICS, 2018, 19
  • [39] SPOP mutation as a predictive marker for treatment of metastatic castration-resistant prostate cancer.
    Stangl, Andrew
    Willner, Christopher
    Maahs, Lucas
    Burmeister, Charlotte
    Hwang, Clara
    Pilling, Amanda
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [40] Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer
    Michael T. Schweizer
    Roman Gulati
    Todd Yezefski
    Heather H. Cheng
    Elahe Mostaghel
    Michael C. Haffner
    Radhika A. Patel
    Navonil De Sarkar
    Gavin Ha
    Ruth Dumpit
    Brianna Woo
    Aaron Lin
    Patrick Panlasigui
    Nerina McDonald
    Michael Lai
    Katie Nega
    Jeannette Hammond
    Petros Grivas
    Andrew Hsieh
    Bruce Montgomery
    Peter S. Nelson
    Evan Y. Yu
    Prostate Cancer and Prostatic Diseases, 2023, 26 : 194 - 200
12345